< Back to Newsroom

MultiCell Technologies Recaps New Investor Conference Call Discussing Recent Drug Development Initiatives and Strengthened IP Portfolio

Investors Invited to Listen to Archived Webcast Now Available Online

SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET - News), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, invites investors to listen to an online webcast of its latest investor conference call in which Dr. Stephen Chang, Chief Executive Officer of MultiCell, discussed the Company's lead therapeutics programs in addition to recent events and progress.

To listen to the webcast recording of the conference call online, free of charge, interested investors can visit http://www.trilogy-capital.com/tcp/multicell/.

"One of the key messages I'd like to stress here is that MultiCell is essentially developing a powerful franchise with respect to treatments for multiple sclerosis," said Dr. Chang during the conference call. "We have two different first-in-class drugs under development, and I believe we are far ahead of the field when it comes to addressing this disease."

Dr. Chang highlighted other key elements of MultiCell's strategy to address a range of widespread immune-based disorders. Among other major achievements he discussed was the recent filing of a milestone patent that provides a potential method for treating a range of malignant tumors using the Company's unique technologies.

"In addition to our promising pipeline of drug candidates, MultiCell also has an increasingly strong intellectual property portfolio," said Dr. Chang. "In fact, we recently announced that our platform technology portfolio now totals 54 issued or pending patents that leverage our breakthrough technology to develop a new generation of therapeutic candidates."

Dr. Chang also outlined MultiCell's strategic initiatives:

• The continued expansion of the Company's portfolio of cutting-edge immune-modulation platform technologies and drug candidates to support product development and capitalize on licensing opportunities.
• The advanced development of the Company's new drug pipeline, particularly with respect to launching Phase IIB/III of human clinical trials of its drug candidate MCT-125 to address global unmet medical needs in multiple sclerosis treatment.
• The continued support for existing research and development programs, and establishment of additional programs and strategic partnerships to ensure success and shorten time to market.

MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics.

For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html.

Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward-looking statements include statements regarding developing products that address unmet medical needs. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

MultiCell Technologies, Inc.
Dr. Stephen Chang, 858.200.0598
MCETInvestor@MultiCelltech.com

or

SmallcapInsights.com
Dr. John Faessel, 858-587-8590
editors@smallcapinsights.com

or

Trilogy Capital Partners (Financial Communications)
Paul Karon, 800-592-6067
paul@trilogy-capital.com


Source: Business Wire (Thursday October 26, 11:43 am ET)